Skip to main content

MALFORMATIONES VASCULARES ONCOGENICAS DESDE LA BIOLOGIA HASTA SU MODELADO

SAF2017-89116-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Functional specialization of different PI3K isoforms for the control of neuronal architecture, synaptic plasticity, and cognition

  • Sánchez-Castillo, Carla
  • Cuartero, María I.
  • Fernández-Rodrigo, Alba
  • Briz, Víctor
  • López-García, Sergio
  • Jiménez-Sánchez, Raquel
  • López, Juan A.
  • Graupera, Mariona
  • Esteban, José A.
  • Sánchez-Castillo, Carla|||/items/03d56d2b-f46a-497a-a442-751626b245e1
Neuronal connectivity and activity-dependent synaptic plasticity are fundamental properties that support brain function and cognitive performance. Phosphatidylinositol 3-kinase (PI3K) intracellular signaling controls multiple mechanisms mediating neuronal growth, synaptic structure, and plasticity. However, it is still unclear how these pleiotropic functions are integrated at molecular and cellular levels. To address this issue, we used neuron-specific virally delivered Cre expression to delete either p110α or p110β (the two major catalytic isoforms of type I PI3K) from the hippocampus of adult mice. We found that dendritic and postsynaptic structures are almost exclusively supported by p110α activity, whereas p110β controls neurotransmitter release and metabotropic glutamate receptor–dependent long-term depression at the presynaptic terminal. In addition to these separate functions, p110α and p110β jointly contribute to N-methyl-d-aspartate receptor–dependent postsynaptic long-term potentiation. This molecular and functional specialization is reflected in different proteomes controlled by each isoform and in distinct behavioral alterations for learning/memory and sociability in mice lacking p110α or p110β.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Functional specialization of different PI3K isoforms for the control of neuronal architecture, synaptic plasticity, and cognition

  • Sánchez-Castillo, Carla
  • Cuartero, María I
  • Fernández-Rodrigo, Alba
  • Briz, Víctor
  • López-García, Sergio
  • Jiménez-Sánchez, Raquel
  • López, Juan A
  • Graupera, Mariona
  • Esteban, José A
Neuronal connectivity and activity-dependent synaptic plasticity are fundamental properties that support brain function and cognitive performance. Phosphatidylinositol 3-kinase (PI3K) intracellular signaling controls multiple mechanisms mediating neuronal growth, synaptic structure, and plasticity. However, it is still unclear how these pleiotropic functions are integrated at molecular and cellular levels. To address this issue, we used neuron-specific virally delivered Cre expression to delete either p110α or p110β (the two major catalytic isoforms of type I PI3K) from the hippocampus of adult mice. We found that dendritic and postsynaptic structures are almost exclusively supported by p110α activity, whereas p110β controls neurotransmitter release and metabotropic glutamate receptor–dependent long-term depression at the presynaptic terminal. In addition to these separate functions, p110α and p110β jointly contribute to N-methyl-D-aspartate receptor–dependent postsynaptic long-term po, This work was supported by the Spanish Ministry of Science and Innovation grants SAF2017-86983-R and PID2020-117651RB (to J.A.E.), Spanish Ministry of Science and Innovation grants SAF2017-89116R-P (FEDER/EU) and PID2020-116184RB (to M.G.), Carlos III Institute of Health-Fondo de Investigación Sanitaria grant PRB3 (IPT17/0019–ISCIII-SGEFI/ERDF, ProteoRed) and CIBERCV (to J.A.L.), Spanish Ministry of Economy postdoctoral contract IJCI-2015-25507 (to M.I.C.), Marie Curie cofund UAM-UE (EU project 713366) Intertalentum Postdoctoral Program (to V.B.), and Spanish Ministry of Science and Innovation predoctoral contracts (to C.S.-C., A.F.-R., and S.L.-G.). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr|||0000-0003-4765-168X
  • Sabata Perez, Helena|||0000-0003-0637-0638
  • Vilalta, Odena
  • Gouveia, Leonor|||0000-0002-3825-8571
  • Angulo-Urarte, Ana|||0000-0002-8024-814X
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo-Escudero, Lucía|||0000-0002-8364-9520
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Lavarino, Cinzia
  • Javierre, B. M.|||0000-0002-8682-6748
  • Celis, Verónica Paola
  • Rovira, Cinzia
  • López-Fernández, Susana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Mora, J.
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3ca activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations.